169 related articles for article (PubMed ID: 38035700)
21. Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 Rearrangements.
Alsharif R; Dunleavy K
Hematol Oncol Clin North Am; 2019 Aug; 33(4):587-596. PubMed ID: 31229156
[TBL] [Abstract][Full Text] [Related]
22. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.
Sander S; Calado DP; Srinivasan L; Köchert K; Zhang B; Rosolowski M; Rodig SJ; Holzmann K; Stilgenbauer S; Siebert R; Bullinger L; Rajewsky K
Cancer Cell; 2012 Aug; 22(2):167-79. PubMed ID: 22897848
[TBL] [Abstract][Full Text] [Related]
23. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
24. Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro.
Han SS; Son DJ; Yun H; Kamberos NL; Janz S
Leuk Res; 2013 Feb; 37(2):146-54. PubMed ID: 23237561
[TBL] [Abstract][Full Text] [Related]
25. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.
Harrington CT; Sotillo E; Robert A; Hayer KE; Bogusz AM; Psathas J; Yu D; Taylor D; Dang CV; Klein PS; Hogarty MD; Geoerger B; El-Deiry WS; Wiels J; Thomas-Tikhonenko A
Leukemia; 2019 Oct; 33(10):2429-2441. PubMed ID: 30914792
[TBL] [Abstract][Full Text] [Related]
26. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
Spender LC; Inman GJ
Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218
[TBL] [Abstract][Full Text] [Related]
27. The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.
Grygalewicz B; Woroniecka R; Rymkiewicz G; Rygier J; Borkowska K; Kotyl A; Blachnio K; Bystydzienski Z; Nowakowska B; Pienkowska-Grela B
Am J Clin Pathol; 2017 Dec; 149(1):17-28. PubMed ID: 29272887
[TBL] [Abstract][Full Text] [Related]
28. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma.
Smith SM; Anastasi J; Cohen KS; Godley LA
Blood Cells Mol Dis; 2010 Dec; 45(4):317-23. PubMed ID: 20817505
[TBL] [Abstract][Full Text] [Related]
29. l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.
Sang W; Tu D; Zhang M; Qin Y; Yin W; Song X; Sun C; Yan D; Wang X; Zeng L; Li Z; Xu K; Xu L
J Biochem Mol Toxicol; 2022 Aug; 36(8):e23117. PubMed ID: 35757978
[TBL] [Abstract][Full Text] [Related]
30. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.
Li T; Song L; Zhang Y; Han Y; Zhan Z; Xv Z; Li Y; Tang Y; Yang Y; Wang S; Li S; Zheng L; Li Y; Gao Y
J Cell Mol Med; 2020 Jun; 24(12):6704-6715. PubMed ID: 32391636
[TBL] [Abstract][Full Text] [Related]
33. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
[TBL] [Abstract][Full Text] [Related]
34. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
[TBL] [Abstract][Full Text] [Related]
35. Cryptic MYC insertions in Burkitt lymphoma: New data and a review of the literature.
Woroniecka R; Rymkiewicz G; Szafron LM; Blachnio K; Szafron LA; Bystydzienski Z; Pienkowska-Grela B; Borkowska K; Rygier J; Kotyl A; Malawska N; Wojtkowska K; Parada J; Borysiuk A; Murcia Pienkowski V; Rydzanicz M; Grygalewicz B
PLoS One; 2022; 17(2):e0263980. PubMed ID: 35167621
[TBL] [Abstract][Full Text] [Related]
36. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma.
Niklinski J; Claassen G; Meyers C; Gregory MA; Allegra CJ; Kaye FJ; Hann SR; Zajac-Kaye M
Mol Cell Biol; 2000 Jul; 20(14):5276-84. PubMed ID: 10866684
[TBL] [Abstract][Full Text] [Related]
37. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
38. In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes.
Opie J; Antel K; Koller A; Novitzky N
Ann Hematol; 2020 Mar; 99(3):571-578. PubMed ID: 31955214
[TBL] [Abstract][Full Text] [Related]
39. SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma.
Jeong SM; Lee A; Lee J; Haigis MC
J Biol Chem; 2014 Feb; 289(7):4135-44. PubMed ID: 24368766
[TBL] [Abstract][Full Text] [Related]
40. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
